Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions

Yongzhi Yang1,2, Peng Junjie1,2, Cai Sanjun1,2, Yanlei Ma1,2*  
1. Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.

* Corresponding author: Dr. Yanlei Ma, Department of Colorectal Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong'an Road, Shanghai, 20032, China, Tel.: +86 21 64175590; Fax: +86 21 54175590, E-mail: yanleima@fudan.edu.cn

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2017.02.24; Accepted: 2017.08.29; Published: 2017.09.15

Abstract
Identification of the colorectal adenoma-carcinoma sequence with its corresponding genetic and epigenetic alterations has significantly increased our knowledge of the etiopathogenesis of colorectal cancer (CRC). However, the molecular mechanisms of colorectal carcinogenesis and metastasis haven't been clearly elucidated. Long non-coding ribonucleic acids (lncRNAs) are key participants of gene regulations rather than "noises". Accumulative studies have implicated that the aberrant expressions of lncRNAs are tightly correlated to CRC screening, diagnosis, prognosis and therapeutic outcomes. Our review focuses on recent findings on the involvement of lncRNAs in CRC oncogenesis and the lncRNA-based clinical implications in patients with CRC.

Key words: Long noncoding RNA (lncRNA); colorectal cancer (CRC); tumorigenesis; biomarker

Introduction

Genomic studies over the past several decades have confirmed that only approximately 2% of human gene transcripts are stably translated into proteins, generating numerous non-protein-coding ribonucleic acids (ncRNAs)[1]. Mounting evidence suggests that these non-coding transcriptional “noises” encompass a wide variety of subclasses, including not only “housekeeping” ncRNAs [(such as ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), small nuclear RNAs (snRNAs, also known as u-RNAs), small nucleolar RNAs (snoRNAs), and Ribonuclease P (RNase P)] but also “regulatory” ncRNAs[2]. The growing numbers of “regulatory” ncRNAs contain two main groups: the short ncRNAs [such as microRNAs (miRNAs), short interfering RNAs (siRNAs), and PIWI-interacting RNAs (piRNAs)] and long noncoding RNAs (lncRNAs)[3]. All of these ncRNAs form a network-like RNA infrastructure[4].

Over recent years, the different subclasses of short regulatory ncRNAs, such as miRNAs, have been relatively well recognized and studied based on their structural features and biologic functions. For example, we previously reported that the elevation of oncofetal miR-17-5p targets the nucleolar and coiled-body phosphoprotein 1 (NOLC1, also known as P130) gene, and subsequently activates the Wnt/β-catenin pathway during oncogenesis and CRC progression[5]. Moreover, the weak miR-150 expression status of CRC patients links with a poorer response to adjuvant chemotherapy and is considered a potential prognostic biomarker in CRC[6].

Most recently, our knowledge has been advanced by the emergence of next-generation sequencing (NGS) technology and the development of bioinformatics methods to investigate lncRNAs[7]. LncRNAs are typically defined as endogenous noncoding RNA molecules (> 200 nucleotides) that govern many genes expressions at the epigenetic, transcriptional, or post-transcriptional levels[8]. Building upon their genomic proximity to protein-coding genes, lncRNAs may be crudely divided into different groups: intergenic transcripts (lincRNAs), intronic transcripts, overlapping transcripts either in sense or in antisense, and...
processing-type transcripts that cannot be placed in any of the other categories\cite{8,10}. The past decade has witnessed a steep rise in interest in IncRNA research. Referring to the latest database, NONCODE v4.0 (http://www.bioinfo.org/noncode/), more than 54,000 and 46,400 IncRNA genes have been identified in humans and in mice, respectively\cite{11}. However, a majority of IncRNAs remain to be characterized. Advances in understanding the basic mechanisms of the involvement of IncRNAs in cancer have raised the field of cancer research well beyond original expectations. Changes of IncRNAs expression profiles have been observed in many human CRC, and such discovery may open a new avenue for the IncRNA-based clinical applications in CRC\cite{12}.

As the fourth leading reason of cancer-related mortality, CRC is associated with tremendous social and economic burden worldwide\cite{13}. The pathogenetic mechanisms underlying CRC development are complex. The “adenoma–carcinoma sequence” multi-step model proposed by Fearon and Vogelstein suggests that accumulating genetic and epigenetic mutations in the colorectum drive epithelial dysplasia and proliferation, ultimately resulting in CRC\cite{14}.

Both intrinsic (such as age, diabetes, obesity, adenomatous polyposis, and inflammatory bowel disease) and extrinsic (such as smoking, inadequate fiber, fish and vitamin D intake, hard-drinking, and high-fat diet) factors have been shown to be associated with CRC risk. Regarding intrinsic factors, We previously conducted a systematic review in approximately 9,000,000 participants from 41 prospective studies\cite{15}. We confirmed that both general obesity and central obesity are positively associated with CRC risk\cite{16}. Regarding extrinsic factors, we previously summarized 9 prospective studies with approximately one million participants for meta-analysis, and found inverse correlation between vitamin D intake/ blood 25-hydroxyvitamin D levels and CRC risk\cite{17}. Moreover, although previous studies have documented the dysregulation of many oncogenes [including the Kirsten rat sarcoma viral oncogene homolog (KRAS) and v-myc avian myelocytomatosis viral oncogene homolog (MYC, also known as c-Myc)] and oncosuppressive genes (including the adenomatous polyposis coli (APC), β-catenin (CTNNB1), deleted in colorectal cancer (DCC) and P53) in CRC, the molecular and genetic basis of colorectal carcinogenesis and metastasis remain largely unknown\cite{18}. Therefore, there is still an urgent need to improve our understanding of the CRC etiopathogenesis and to develop additional tumor markers and therapeutic targets for this disease.

In this review, we will first provide an overview of the biology and function of IncRNAs. We will then focus on the involvement of IncRNA dysregulation in CRC etiopathogenesis. Finally, we will discuss the latest advance of the clinical implications of IncRNAs and their association with the diagnosis, prognosis and potential treatment of CRC.

Origins and functions of IncRNAs

Understanding the origins and molecular mechanisms of IncRNAs is critical for characterizing IncRNA function. The emergence of functional noncoding RNAs can be divided into the following non-mutually exclusive hypotheses\cite{18}: (1) frame disruptions of a protein-coding gene generates a IncRNA; (2) two untranscribed and divided sequences are juxtaposed following chromosomal rearrangement and are transformed into a multi-exon IncRNA; (3) duplication of a noncoding gene following retrotransposition gives rise to IncRNAs; (4) tandem duplication events of neighboring repeats give rise to a IncRNA; and (5) a transposable element (TE) inserted into a gene emerges as a new IncRNA. However, the origins of many IncRNAs remain elusive except for several typical transcripts, such as X-inactive specific transcript (Xist). Recent studies reported by Derrien at al\cite{10} and Ulitsky at al\cite{19} suggest that a novel IncRNA gene can occur de novo either from untranscribed sequence or from TE, which is in contrast to protein coding genes.

While the origin and evolution of IncRNAs are still obscure, even less is known regarding their precise molecular functions. Although previously regarded as “junk DNA” because of their overwhelming burden of transposons, pseudogenes, and simple repeats, there is mounting evidence that IncRNAs exert a diverse spectrum of regulatory functions, including X chromosome inactivation (XCI), genomic imprinting, tissue regeneration, cell cycle control, apoptosis, aging and carcinogenesis\cite{1,20}.

To better understand their functional significance, IncRNAs can be further reclassified based on their molecular mechanisms into following categories (Figure 1): (1) signaling molecules (e.g., Xist, lincRNA-p21, COLDAIR, or HOTAIR), which are transcribed in a time- or space-specific manner in response to diverse stimuli, and reflect the integrated transcriptional activity; (2) molecular decoys (e.g., MALAT1, PTENP1, IPS1 or PANDA), which bind and competitively inhibit transcription factors, miRNAs or other targets from chromatin, but do not exert any additional functions; (3) molecular guides (e.g., Xist, COLDAIR, lincRNA-p21 or HOTAIR), which can recruit chromatin-modifying enzymes to specific target sequences, either in cis or in trans; and (4) molecular scaffolds (e.g., TERC, HOTAIR, ANRIL),
which can work as central platforms and assemble proteins together to form architecture of ribonucleoprotein complexes\(^{[21]}\). In fact, several lncRNAs have multiple modes of action that are critical to their biological function\(^{[21]}\). For example, the Hox transcript antisense intergenic RNA (HOTAIR), located at chromosome 12q13.13, is a lincRNA that may function not only as an anatomic signal that guides chromatin-modifying complexes to their targets but also as a molecular scaffold for histone modification complexes\(^{[9]}\). Thus, it is apparent that the molecular mechanisms of genes regulation and cellular functions mediated by lncRNAs may be far more sophisticated than by miRNAs.

**Methods of lncRNA detection or quantification**

Several techniques are currently available that can be used for lncRNA detection and quantification, including RNA sequencing (RNA-seq), RNA microarray, reverse transcription polymerase chain reaction (RT-PCR), fluorescence *in situ* hybridization (FISH), and RNA blot analysis\(^{[12]}\). Most lncRNAs operate as RNA-protein complexes, and advanced methods for studying lncRNA-protein interactions include the following: RNA interference (RNAi), RNA Pull-down, RNA-binding protein immunoprecipitation (RIP), chromatin isolation by RNA purification (ChIRP), ChIRP-sequencing (ChIRP-seq), crosslinking-immunopurification (CLIP) and CLIP-sequencing (CLIP-seq)\(^{[22]}\).

Meanwhile, the available computational approaches and bioinformatics resources allow researchers to better characterize the functional lncRNAs and to shed additional light on the roles of lncRNAs in CRC\(^{[23]}\). The related database, annotation tools and other bioinformatics resources available are listed in Table 1.

**lncRNA expression profiles in CRC**

Research focused on the molecular mechanisms of CRC has highlighted the stepwise progression following the adenoma-carcinoma sequence. Accumulated evidence indicates that CRC-associated lncRNAs acts as master gene regulators through different mechanisms. With the aid of tools ranging from global lncRNA expression profiles with RNA-seq or RNA microarray to selected lncRNAs expression examining with qRT-PCR or FISH, several studies have detected a number of consistently and reproducibly altered CRC-associated lncRNAs both *in vivo* and *in vitro*\(^{[38-42]}\).

The first CRC-related lncRNA was identified in 1996 when Hibi and colleagues\(^{[43]}\) reported that the endogenous H19 gene is frequently abundant in CRC specimens, and the overexpression of H19 plays an important role in CRC development. Since that discovery, accumulating reports of dysregulated expression of lncRNAs in CRC have suggested that aberrant lncRNAs are involved in all stages of CRC (Table 2). Recent studies are aimed at determining whether lncRNAs can be used as novel predictors for CRC screening, diagnosis, prognosis and therapeutic outcomes.

---

**Figure 1. Schematic representation of the molecular mechanisms of four categories of lncRNAs.**

**A.** Molecular signals: such lncRNAs are transcribed in a time- or space-specific manner to respond to diverse stimuli and reflect the integrated actions of transcription factors; **B.** Molecular decoys: such lncRNAs bind and titrate away transcription factors, miRNAs or other targets from chromatin; **C.** Molecular guides: such lncRNAs can recruit chromatin-modifying enzymes to specific targets, either in cis or in trans; **D.** Molecular scaffolds: such lncRNAs can work as central platforms and assemble proteins to form architecture of ribonucleoprotein complexes.
Table 1. The lncRNA bioinformatics resources.

| Bioinformatics Resources | Web Link | Reference |
|--------------------------|----------|-----------|
| NONCODE v4               | http://www.noncode.org | [24]       |
| HT-invDB rel 8.3          | http://www.h-invitational.jp | [25]       |
| LncRNADisease             | http://cmbi.bjmu.edu.cn/lncrnadisease | [26]       |
| LincSNP                   | http://bioinfo.hrbmu.edu.cn/LincSNP | [27]       |
| Rfam 11.0                 | http://rfam.janelia.org | [28]       |
| Human Body Map lincRNAs   | http://www.broadinstitute.org/genome_bio/human_lincrnas/ | [29]       |
| IncRNAdb                  | http://www.lncrnadbi.org/ | [30]       |
| ncFANs                    | http://www.ebiomed.org/ncFANs/ | [31]       |
| Noncoder                  | http://noncoder.mpib.mpg.de | [32]       |
| NRED                      | http://nred.matticklab.com/cgi-bin/incrnadb.pl/ | [33]       |
| ChIPBase                  | http://deepbase.sysu.edu.cn/chipbase/ | [34]       |
| LNCipedia 2.0             | http://www.lncipedia.org/ | [35]       |
| DIANA-LncBase             | http://www.microrna.gr/LncBase/ | [36]       |
| iSeeRNA                   | http://www.myogenesisdb.org/iSeeRNA/ | [37]       |

Table 2. LncRNAs associated with CRC.

| LncRNAs and references | Cytoband | Expression level | Types | Mode of action | Potential clinical significance |
|------------------------|----------|-----------------|-------|---------------|--------------------------------|
| CCAT1[41]              | 3q29     | Elevated        | Oncogenic | Activates Wnt signaling by suppressing AP-2α | Prognosis and therapeutics |
| CCAT1[38, 42, 45]      | 8q24.21  | Elevated        | Oncogenic | N/A | Screening, diagnosis, and prognosis |
| CCAT1[41]              | 8q24.21  | Elevated        | Oncogenic | Regulates chromatin interactions at the MYC locus | Prognosis |
| CCAT2[46]              | 8q24.21  | Elevated        | Oncogenic | Up-regulates and Responds to Wnt signaling; underlies metastatic progression and chromosomal instability | Prognosis and diagnosis |
| CRNDE[47, 48]          | 16q12.2  | Elevated        | Oncogenic | Responds to EGF signaling; regulates genes involved in central metabolism | Prognosis |
| E2F antisense[49]      | 16q21-22 | Elevated        | Oncogenic | Activated by Wnt signaling; contributes to carcinogenesis by reducing the level of the E2F4 cell cycle repressor | Prognosis and diagnosis |
| HOTAIR[39, 50]         | 12q13.13 | Elevated        | Oncogenic | Correlates with PRC2 function; participates in EMT | Screening, diagnosis, and prognosis |
| HULC[51]               | 6p24.3   | Elevated        | Oncogenic | N/A | Prognosis |
| KCNQ1OT1/LIT1[52, 53]  | 11p15.5  | LOI             | Oncogenic | Correlates with epigenetic status at the KvDMR1 locus | Prognosis and diagnosis |
| IncRNA-ATB[54]         | 14q11.2  | Elevated        | Oncogenic | Activated by TGβ-β; promotes EMT | Prognosis and diagnosis |
| MALAT[55]              | 11q31.2  | Elevated        | Oncogenic | Promotes EMT by regulating ZEB1, ZEB2 and Slug expression; activates Wnt signaling | Prognosis and diagnosis |
| ncNRF[56]              | 1p13.2   | Elevated        | Oncogenic | Inhibits the oncosuppressive function of let-7 by binding to target mRNAs | Prognosis |
| PCAT[57]               | 8q24.21  | Elevated        | Oncogenic | Generates antiapoptotic activity via TGF-β signaling | Prognosis |
| PVT1[58]               | 8q24     | Elevated        | Oncogenic | Reduces apoptosis | Prognosis, prognosis, and therapeutics |
| uc.73A[59]             | 2q22.3   | Elevated        | Oncogenic | Suppresses CRC proliferation via targeting p21 | Prognosis and diagnosis |
| CUDR[60]               | 19p13.12 | Elevated        | Oncogenic | N/A | N/A |
| BANCR[61]              | 9q21     | Decreased       | Onco suppressive | Repressed by histone deacetylase 3; contributes to hypoxia-mediated metastasis | N/A |
| CAHNR[62]              | 6q26     | Decreased       | Oncosuppressive | N/A | Screening and diagnosis |
| IncRNA-LET[63]         | 15q24.1  | Decreased       | Oncosuppressive | N/A | N/A |
| lincRNA-p2[64]         | 6p21.2   | Decreased       | Oncosuppressive | Acts with hnRNP-K as a transcriptional coactivator of p53 | Prognosis |
| Lox285194[65, 66]      | 3q13.31  | Decreased       | Oncosuppressive | Induced by p53; inhibits tumor cell growth in part through reducing miR-211 level | Prognosis |
| MEG3[67, 68]           | 14q32.2  | Decreased       | Oncosuppressive | Induces accumulation of TP53 by down-regulating MDM2 | N/A |
| ncRAN[69]              | 17q25.1  | Decreased       | Oncosuppressive | N/A | Prognosis and therapeutics |
| PTENP1[70]             | 9p13.3   | Decreased       | Oncosuppressive | Regulates cellular levels of PTEN by binding to the PTEN-targeting miRNAs | Prognosis and therapeutics |
| BA318C17.1[71]         | 20p12.1  | Decreased       | Oncosuppressive | N/A | Prognosis |
| H19[40, 72, 73]        | 11p15.5  | Elevated or LOI | Oncogenic/ Onco suppressive | Decreases RB expression by acting as the precursor of miR-675; controls the number of polyps in the APC murine model of CRC; promotes EMV via functioning as miR-138 and miR-200a sponges | Prognosis and therapeutics |
| PRNCR1[68]             | 8q24     | N/A             | N/A | Contains CRC-related SNPs within its locus | Screening |
| XIST[74, 75]           | Xq13.2   | Elevated        | N/A | N/A | N/A |

http://www.jcancer.org
Involvement of IncRNAs in CRC pathogenesis

It is widely accepted that CRC tumorigenesis is a multistage process\(^\text{[76]}\). CRC develops typically from normal mucosal epithelium to a benign adenoma and ultimately progresses to malignant tumor\(^\text{[77]}\). Understanding the tumorigenic signaling pathways that involve IncRNAs would provide further insights into CRC pathogenesis.

IncRNAs participate in many known signaling pathways involved in CRC pathogenesis, including the Wnt/β-catenin signaling pathway, epidermal growth factor receptor (EGFR)/insulin-like growth factor type I receptor (IGF-IR) signaling pathway (KRAS and phosphatidylinositol-3-kinase (PI3K) pathways), transforming growth factor-beta (TGF-β) signaling pathway, p53 signaling pathway, and the epithelial–mesenchymal transition (EMT) program (Figure 2).

The Wnt/β-catenin pathway

The disruption of the Wnt/β-catenin pathway contributes to CRC initiation\(^\text{[78]}\). The β-catenin destruction complex, comprising of multi-protein like Axin, Glycogen Synthase Kinase 3β (GSK-3β), APC, casein kinase 1 (CK1), protein phosphatase 2A (PP2A), activator protein 2α (AP-2α), are switch controls for Wnt signaling\(^\text{[79]}\). Malfunction of this destruction complex leads to stimulation of the Wnt signaling via the translocation of accumulated free β-catenin into the nucleus and subsequent activation of T-cell factor (TCF)/lymphoid enhancing factor (LEF) targets, such as cyclin D1 (CCND1), E2F transcription factor-4 (E2F4), and proto-oncogene c-Myc\(^\text{[80]}\).

![Figure 2. Involvement of IncRNAs in the “adenoma–carcinoma sequence”, multi-step model of CRC pathogenesis.](http://www.jcancer.org)
Inactivation of the oncosuppressive gene APC is the main rate-limiting step of Wnt signaling, occurring in more than 80% of sporadic CRCs[78, 81]. The APC gene has been reported to be modulated by a lncRNA called H19[72], H19 is a paternally imprinted and maternally expressed transcript located at 11p15.5[82]. Oncofetal H19 is elevated during embryogenesis, but is inactivated postnatally and re-expressed during tumorigenesis[83]. Based on their findings that H19 knockout mice never spontaneously develop tumors, Yoshimizu et al. demonstrated that H19 acts as an oncosuppressive gene rather than an oncogene[72]. Meanwhile, in the absence of H19 expression in the APC mutant CRC murine model, the number of adenomas, especially smaller polyps, were significantly higher than in its presence, suggesting that H19 could control the early event of CRC tumorigenesis[72].

AP-2α belongs to β-catenin destruction complex[84]. In vivo and in vitro studies showed that AP-2α served as a oncosuppressive protein by interacting with APC and β-catenin[84]. One of our recent study has shown that new-found colorectal cancer-associated lncRNA (CCAL) negatively regulated AP-2α and then opened the way to Wnt signaling in CRC tumorigenesis[44].

The E2F family of transcription factors are in charge of the cell cycle (G1/S transition) and the action of oncosuppressive genes[85]. Yochum and colleagues[49] revealed a β-catenin-regulated lncRNA derived from the E2F4 locus termed E2F4 antisense transcript. E2F4 antisense transcript is expressed in HCT116 β-catenin signaling-stimulated CRC cells[49]. Both β-catenin and TCF4 could bind to the 3’-untranslated region (3’-UTR) sequences of E2F4, driving expression of this lncRNA that reduces E2F4 levels and decreases binding of E2F4 to promoters of targets such as proliferating cell nuclear antigen (PCNA) and cyclin A2, ultimately activating the expression of genes repressed by E2F4[49].

The MYC region upstream contains an large tumor-type-specific super enhancer[86]. Xiang et al.[41] showed a super-enhancer located at locus 8q24.21, 515 kb MYC upstream region, that transcribes a human CRC-specific lncRNA CCAT1-L. CCAT1-L is known as an isoform of the recently described lncRNA colon cancer-associated transcript-1 (CCAT1)[87], which is exclusively localized to the nucleus, and its expression is upregulated in CRC cell lines and CRC tissue samples[41]. Furthermore, CCAT1-L participates in a positive control of MYC transcription by interacting with a zinc finger protein, CCCTC-binding factor (CTCF), and facilitating CTCF binding to MYC locus[41]. In addition, Ling et al.[46] concluded that a novel gene transcript named colon cancer-associated transcript-2 (CCAT2), which maps to the 8q24.21 genomic region, is a downstream target of Wnt. CCAT2 is overexpressed in microsatellite-stable (MSS) CRC samples[46]. Higher MYC expression was found in CRC cells overexpressing CCAT2, and transient knockdown of CCAT2 reduced MYC expression[46]. Additionally, there is a complex feedback loop between CCAT2 and Wnt signaling. On the one hand, CCAT2 could broadly enhance Wnt activities by binding to TCF-L2, modulating its transcriptional activity[46]. On the other hand, TCF-L2 knockdown consistently reduced CCAT2 expression, indicating that TCF-L2 is necessary for the maintenance of high CCAT2 expression levels[46].

The observations described above suggest that alteration of lncRNA expression participates in the early event of the etiopathogenesis of CRC.

**EGFR/IGF-IR signaling (KRAS and PI3K pathways)**

The epidermal growth factor receptor (EGFR) is one of the members of human EGFR family of receptor tyrosine kinases[88]. Functional stimulation of their receptors occurs in a broad spectrum of solid tumors including CRC[88]. Like EGFR, insulin-like growth factor-I receptor (IGF-IR) is also a ubiquitous transmembrane tyrosine kinase that plays crucial roles in colorectal tumorigenesis and progression[89].

Binding of their respective ligands to the EGFR and IGF-IR lead to their autophosphorylation and subsequent activation of the KRAS/Raf/mitogen-activated protein kinase (MAPK) and PI3K/AKT/mammalian target of rapamycin (mToR) signaling cascades, contributing to uncontrolled cellular proliferation, adhesion, angiogenesis, migration, metastasis, and survival[90].

The newly identified IGF driven gene termed colorectal neoplasia differentially expressed (CRNDE), located at locus hCG_1815491 on chromosome 16, is activated early in CRC and potentially interacts with chromatin-modifying complexes to engage in gene expression[47]. Ellis et al.[48] reported that CRNDE is one of the downstream targets of both the PI3K and KRAS signal cascades. Upregulation of CRNDE expression promotes the metabolic shift of neoplastic colon cells from oxidative metabolism to aerobic glycolysis, contributing to the “Warburg effect”, a hallmark of CRC cell metabolism[48].

Another lncRNA that is involved in the pathogenesis of CRC is a pseudogene called phosphatase and tensin homolog pseudogene 1 (PTENP1) located at 9p13.3 [91]. PTENP1 is highly homologous to the crucial tumor-suppressor gene PTEN, an inhibitor of PI3K pathway signaling[70].

http://www.jcancer.org
Poliseno et al.\textsuperscript{[70]} showed that the bona fide tumor suppressor gene \textit{PTENP1}, which contains a relatively shorter 3'UTR than that of \textit{PTEN}, functions as a decoy to bind to the PTEN-targeting miRNAs, allowing for the expression of the PTEN protein. Moreover, deletion of \textit{PTENP1} in CRC directly correlates with reduced \textit{PTEN} expression\textsuperscript{[70]}.

The TGF-β signaling pathway

TGF-β is a 25-kDa cytokine that signals via transmembrane serine-threonine kinase receptors (STKR) and intracellular mediators of Smad family\textsuperscript{[92]}. The TGF-β signal pathway plays dichotomous roles in the CRC progression\textsuperscript{[93]}. In the early phase of tumorigenesis, TGF-β signaling acts as a cancer suppressor. In contrast, in the late cancer stages, it accelerates CRC invasiveness. Improved understanding of how the TGF-β signaling cascade mediates interactions with lncRNA will provide important insights into colorectal carcinogenesis, development and progression\textsuperscript{[84]}

Some researchers have demonstrated the involvement of lncRNAs in TGF-β signaling pathways that are associated with various cancer types, including CRC\textsuperscript{[50]}. TGF-β signaling is induced by the aberrant expression of lncRNAs. The human \textit{PVT-1} oncogene, which encodes the lncRNA \textit{PVT-1}, is involved in cancer pathophysiology\textsuperscript{[95]}. Takahashi and colleagues\textsuperscript{[58]} conducted gene expression microarray analyses using \textit{PVT-1} knockdown of CRC cell lines RKO and HCT116 and found that the proteins relating to the canonical TGF-β signaling (such as tumor suppressor gene Smad4) and apoptosis were significantly activated by \textit{PVT-1} knockdown.

On the other hand, lncRNAs can also be activated by TGF-β. For example, Yuan and colleagues\textsuperscript{[84]} discovered a novel TGF-β-induced lncRNA termed lncRNA-activated by TGF-β (\textit{lncRNA-ATB}) that promotes the invasion-metastasis cascade in hepatocellular carcinoma through Smad-independent signaling. \textit{lncRNA-ATB} competitively binds to and sponges miR-200s away from their mRNA targets, zinc-finger E-box binding homeobox family proteins (including ZEB1 and ZEB2), which encode the key EMT-promoting transcription factors, thus promoting EMT\textsuperscript{[84]}. Notably, \textit{lncRNA-ATB} is also significantly upregulated by TGF-β in the Smad4-deficient CRC cell line SW480, indicating that \textit{lncRNA-ATB} also promotes CRC progression through the noncanonical TGF-β pathway\textsuperscript{[50, 54]}

Taken together, these findings suggest an existence of a complex feedback loop between the lncRNAs and the TGF-β signaling pathway.

The p53 pathway

The tumor suppressor p53, known as “a cellular gatekeeper”, provides an intrinsically powerful defense against CRC. As a master transcription factor, p53 not only upregulates anti-proliferative and proapoptotic genes such as cyclin-dependent kinase inhibitor 1 (p21) (G1 arrest), cyclin B1 (G2 arrest), p53-upregulated modulator of apoptosis (PUMA; apoptosis) and the plasminogen activator inhibitor 1 (PAI-1; cellular senescence), but it also suppresses the genes involved in control of cell proliferation such as polo-like kinase-1 (PLK1) and apoptosis (Bcl-2)\textsuperscript{[96, 97]}

Loss of p53 function, through either mutations in p53 itself or perturbations in pathways signaling to p53, is a frequent alteration in the majority of human cancers, including CRC\textsuperscript{[61]}

Strong evidences have unraveled the link between p53 and the lncRNA network\textsuperscript{[98]}. Several lncRNAs, such as \textit{MEG3}, \textit{MALAT1}, \textit{p53-eRNAs}, and \textit{Wrap53}, serve as p53 regulators, while other lncRNAs, such as \textit{Loc285184}, \textit{Incrna-p21}, \textit{H19}, and \textit{PANDA}, serve as p53 effectors\textsuperscript{[99]}. For example, the human maternally expressed gene-3 (MEG3), with a length of 1595 nucleotides, is an imprinted ncRNA located at human 14q32.3\textsuperscript{[100]}. As a p53 regulator, \textit{MEG3} downregulates expression of the well-known negative p53 regulator, mouse double minute 2 homolog (MDM2), selectively regulates p53 targets expression, ultimately inhibiting CRC pathogenesis and progression\textsuperscript{[67]}. Furthermore, the expression of \textit{MEG3} is under epigenetic control, and because of hypermethylation in the \textit{MEG3} promoter, \textit{MEG3} loss is common in many human tumors (including CRC) and tumor cell lines (including colon cell lines HCT116 and H29)\textsuperscript{[67, 68, 101, 102]}. Thus, \textit{MEG3} could represent a tumor suppressor gene.

Unlike the p53 regulator \textit{MEG3}, the lncRNA \textit{Loc285194} (also referred to as LSAMP antisense RNA 3) serves as a p53 effector. The \textit{Loc285194} gene, located at 3q13.31 and consisting of 4 exons for a total of 2105 nt in length, was originally identified to be downregulated in osteosarcoma samples and subsequently reported to be downregulated in CRC\textsuperscript{[66]}. Through \textit{in vitro} and \textit{in vivo} analyses, Liu and colleagues\textsuperscript{[65]} further reported that the \textit{Loc285194} upstream region is a putative transcription target of p53. As an endogenous splice, \textit{Loc285194} inhibits CRC cell growth by binding to and repressing oncogenic miR-211\textsuperscript{[65]}. These results imply \textit{Loc285194} as a potential CRC suppressor.

In addition to \textit{Loc285194} expression, which is triggered by p53, Huarte and colleagues\textsuperscript{[103]} identified a p53-activated lncRNA called \textit{lncRNA-p21} that played an important role in triggering apoptosis. \textit{lncRNA-p21} is also a direct p53 transcription target.
near the cyclin-dependent kinase (CDK) inhibitor p21 (CDKN1A) locus, a canonical transcriptional target of p53[104]. Loss of lincRNA-p21 affects many genes that are usually suppressed by p53, whereas expression of this lincRNA functions as a transcriptional repressor by modulating the localization of heterogeneous nuclear ribonucleoprotein K (hnRNP-K), a well-known inhibitor complex in the p53 pathway[103].

In light of these findings, we conclude that lncRNAs also belong to the p53-regulatory network and are involved in CRC tumorigenesis.

The EMT program

Distant metastasis is the primary cause of CRC-related mortality[105]. Recent preclinical or clinical research has implicated the activation of the EMT program and its reverse program in the metastatic process in CRC[106]. The hallmarks of EMT include the downregulation of E-cadherin (CDH1) and upregulation of non-epithelial cadherins, like N-cadherin (CDH2)[10]. Several reasons contribute to the disturbance of controlled epithelial balance, including the altered expression levels of lncRNAs[107].

Several researches have highlighted the roles of lncRNAs in regulating the epithelial phenotype by controlling EMT inducers such as ZEB1, ZEB2 and Snail zinc finger family proteins [including Snail1 and Snail2 (also known as Slug)][108]. For example, metastasis-associated lung adenocarcinoma transcript-1 (MALAT1) has been confirmed to be an important mediator of TGF-β-induced EMT[109]. Upregulated MALAT1 promotes EMT by regulating expression levels of ZEB1, ZEB2 and Slug and activating Wnt signal during the metastasis of bladder cancer[110]. Because the overexpression of MALAT1 was previously confirmed to be involved in CRC progression, we hypothesized that MALAT1 may also play critical roles in CRC cell EMT programs; this hypothesis remains to be validated.

A second lncRNA functioning as a positive moderator of EMT progression in CRC is H19. H19 was found to be upregulated in two EMT model, including Methotrexate (MTX) resistant HT-29 CRC cell, TGF-β1-treated HT-29 CRC cell and TGF-β1-treated SW620 CRC cell[73]. H19 modulated ZEB1 and ZEB2 expression levels by functioning as decoys for miR-138 and miR-200a, promoting EMT transition in CRC[73]. Moreover, lncRNA H19 enhanced the invasive potential of cancer cells by inhibiting E-cadherin via induction of the expression of miR-675-dependent Slug[107].

A third lncRNA participating in EMT-controlled CRC metastasis is called HOTAIR. Wu and colleagues[111] revealed that HOTAIR overexpression promotes CRC cell migration and invasiveness, while depletion of HOTAIR suppresses the EMT program, including upexpression of E-cadherin and loss of vimentin and matrix metalloproteinase-9 (MMP9). These examples demonstrate the functional importance of lncRNAs in invasion and metastasis.

Clinical implications of lncRNAs in CRC

Effect of above-mentioned lncRNAs in CRC etiopathogenesis clearly revealed that dysregulated lncRNAs in CRC may be of significant clinical value (Figure 3). Several lncRNAs have emerged as promising biomarkers for susceptibility screening, diagnosis, prognosis, and lncRNA-based therapies for CRC[12]. Specifically, polymorphisms within lncRNAs encompass regions that may contri-

Figure 3. Potential use of lncRNAs in CRC screening, diagnosis, prognosis, and treatment. First, Polymorphisms within lncRNA-encompassing regions may contribute to susceptibility to CRC; second, lncRNAs isolated from blood samples may be substantial biomarkers for early diagnosis and prognosis of CRC; third, the aberrant lncRNA expression in CRC correlates with patient survival or treatment outcome, providing the theoretical rationale for using lncRNAs as promising therapeutic targets.
but to susceptibility to CRC, and circulating lncRNAs may be promising markers for the early detection of CRC. Meanwhile, the fact that abnormal lncRNA expression in CRC correlates with patient survival or treatment outcome provides the theoretical rationale for utilizing lncRNAs to be promising therapeutical targets.

**Polymorphisms within lncRNA-encompassing regions as susceptibility screening markers**

Genome-wide association studies (GWAS) combined with single nucleotide polymorphism (SNP) arrays and NGS technology have identified powerful associations of multiple variants, such as SNPs and other genetic abnormalities located on the chromosomal region 8q24 with the onset of CRC[112]. Several highly conserved lncRNAs were discovered to be transcribed from the "gene-desert" region of 8q24[46, 68, 113]. Therefore, oncogenic SNPs located within these lncRNAs transcripts may involve in CRC carcinogenesis.

For instance, the lncRNA CCAT2, which maps to the 8q24.21 region, encompasses a cancer-related rs6983267 SNP that is faithfully linked to CRC oncogenesis, progression, and prognosis through regulating MYC transcription[46]. Using pyrosequencing data on heterogeneous cell lines (DLD1 and KM12SM cells) and CRC samples, Ling et al.[46] found that the G allele of rs6983267 produces more CCAT2 transcripts and induces higher MYC expression than the T allele. The variant genotype of rs6983267 affects the expression levels and functions of CCAT2, providing an alternative explanation of the risk of SNP-conferred CRC.

A second lncRNA involved in cancer-related gene polymorphisms is known as prostate cancer non-coding RNA-1 (PRNCR1). Li et al.[68] identified 4 new functional CRC susceptibility variants (rs13252298, rs7007694, rs16901946, and rs1456315) in the lncRNA PRNCR1 at the 8q24 locus. The authors further demonstrated that the rs13252298 and rs1456315 alleles may contribute to a decreased CRC risk, whereas polymorphisms of the others may promote CRC growth and differentiation [68]. This evidence suggests that SNPs in the lncRNA locus likely increase CRC susceptibility.

Considering the results of these two studies, it is anticipated that with further information from GWAS, more polymorphisms in the lncRNA locus will be discovered, allowing clinicians to better assess the genetic susceptibility to CRC screening.

**Potential of lncRNA expression in CRC early diagnosis**

Due to the screening of fiber-optic colonoscopies, fecal occult blood test (FOBT), and stool-based DNA assays, 5-year CRC-related mortality rates have slightly declined to date. Nonetheless, colonoscopies are invasive and cost intensive, whereas FOBT and stool-based DNA assays have hyposensitivity and low specificity. Until now, only a few functionally characterized serum candidates, such as carcino-embryonic antigen (CEA) and carbohydrate antigen 19-9 (CA-19-9), have been clinically utilized. However, neither CEA nor CA19-9 meets expectations for early detection or prognosis of CRC. Consequently, there is an urgent need for seeking novel biomarkers which are sensitive or specific enough.

Compared with the protein-coding RNAs or their proteins, the use of a lncRNA as a biomarker is of great advantage because its expression is a better indicator of tumor status[114]. The lncRNA expression patterns, either in tissues or in circulation, have the potential to be diagnostic markers for CRC in clinical routine and could lessen the number of unnecessary colonoscopies follow-up procedures.

For example, Tanaka and coworkers[52] found a lncRNA termed long QT intronic transcript-1 (LIT1/KCNQ1OT1) which was frequently (40%) detected to be loss of imprinting (LOI) in the CRC tissues, whereas negative in peritumoral samples. Coincidentally, Nakano et al.[53] supported the fact that LOI of LIT1 was observed only in CRC tissue specimens at a high frequency (53%), but negative (0%) in adjacent normal samples, thereby making LIT1 a potential for the diagnosis of CRC.

Furthermore, Pedersen et al.[68] reported that the lncRNA called colorectal adenocarcinoma hypermethylated (CAHM) was hypermethylated in 81% of adenomas and 71% of CRC but not in normal tissue (8%); meanwhile, methylated CAHM was observed in the plasma of 55% of CRC compared with 4% of adenomas and 7% of subjects without neoplasia, showing the promise of CAHM as a blood candidate for early detection of CRC.

Another potentially diagnostic lncRNA is CRNDE[47]. Graham and colleagues[47] reported that CRNDE upregulation is an early event in CRC. In tissue samples, the expression levels of the CRNDE transcript were found to be elevated in more than 90% of tissues from colorectal adenomas and adenocarcinomas, whereas levels were very low in normal tissues or inflammatory bowel disease (IBD) samples. In plasma samples, CRNDE transcript was positive in 13 of 15 CRC patients but in only 1 of 15 controls, affording a sensitivity and specificity of 87% and 93%[47].

Moreover, CCAT1 is another promising RNA biomarker candidate[62]. The 2628 nucleotide-long
IncRNA CCAT1, located in the vicinity of c-Myc on chromosome 8q24.21, was first identified from blood and fecal samples from CRC patients in 2005[113]. Studies from the same group subsequently examined the CCAT1 levels in human biospecimens and found out that CCAT1 was markedly upregulated across the colon adenoma-carcinoma sequence[45]; meanwhile, peripheral blood samples of CCAT1 was shown to be overexpressed (up to 1700 fold) in approximately 40% of CRC, but not in that of healthy volunteers[42]. The researchers first described the use of a CCAT1-specific peptide nucleic acid (PNA)-based molecular beacons (TO-PNA-MB) to be a powerfulpredictor for specific identification of CRC in vitro, ex vivo, and in vivo[38].

Taken together, the ectopic presence of these IncRNAs in tissues, stools, and blood samples raise hope for using combining optimized IncRNAs for detection of CRC.

**Potential of IncRNA expression for CRC prognosis and prediction**

Currently, the only comprehensive criteria employed in clinical practice to provide an indication of CRC prognosis or to guide adjuvant chemotherapy choices is the American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging system[116]. Regrettably, the TNM system hasn’t provided the clinicians with the optimal staging allocation, but has resulted in substantial under- or over-treatment of certain CRC patients over the past decades[117, 118].

Recent studies suggest that both onco-suppressive and oncogenic IncRNAs may have potential to be used as efficient biomarkers of CRC in clinical routine.

For example, Zhai et al.[64] revealed a contradiction regarding the function of tumor suppressor *lincRNA-p21* in CRC progression. On the one hand, the expression levels of *lincRNA-p21* in CRC tissue samples were significantly lower compared with the tumor-adjacent samples. On the other hand, as the CRC stage progresses, the expression levels of this lncRNA in tumor tissues were significantly elevated[64]. The finding indicates that the disruption of the p53/ *lincRNA-p21* network may contribute to CRC development and malignant transformation[64]. Another notable candidate is non-coding RNA expressed in aggressive neuroblastoma (*ncRAN*). This IncRNA located at 17q25.1 is dramatically downregulated in CRC tissues and CRC cell lines, such as DLD1, LoVo and HCT116[69]. Moreover, decreased expression of *ncRAN* leads to CRC metastasis and is correlated to poorer overall survival (OS) in CRC patients[69]. A third example of a tumor suppressive IncRNA is Loc285194. Qi et al[66] showed that the prevalent loss of Loc285194 in CRC tumor tissues was positively related to a larger tumor size, a poorer TNM stage, an increased number of distant metastases and a poorer disease-free survival (DFS)[66]. Hence, Loc285194 might function as a novel prognostic indicator in CRC.

Apart from tumor suppressive lncRNA, the group of oncogenic IncRNAs whose expression is increased may also serve as potential prognostic factors for CRC.

For example, Kogo et al.[39] found that the upregulation of *HOTAIR* was frequent in stage IV CRC tissues with liver metastases. Using gene set enrichment analysis, the authors further revealed that *HOTAIR* expression was significantly correlated to the polycomb-repressive complex-2 (PRC2) gene function, thus contributing globally to cancer progression[39, 119]. Ge et al[57] reported that the IncRNA prostate cancer-associated ncRNA transcript-1 (*PCAT1*) gene, located on the chromosome 8q24 725 kb upstream of the c-Myc, was more frequently upregulated in CRC tumor tissues than in normal adjacent tissues. Moreover, upregulation of *PCAT1* implied a poorer OS time in patients with CRC[57]. Therefore, this IncRNA may be used to complement the TNM staging system to predict prognosis[57]. Our recent study shown that overexpression of IncRNA CCAL in tumor tissues of patients with CRC was connected with a poorer OS and a worse therapeutic outcome, implying CCAL as good indicator for guidence of clinical chemotherapy.

Compared with single utilization mode, the ensemble features of IncRNAs may have an obvious advantage for CRC prognosis. For example, Hu and colleagues[120] performed a IncRNA expression profiling in large CRC cohorts, identifying a set of six IncRNAs (AK024680, AK123657, CR622106, BX649059, BX648207, and AK026784) that correlated with the DFS of CRC. Based on this finding, the authors successfully classified CRC patients into high- or low-risk subgroup for survival prediction[120]. Furthermore, the six-IncRNA signature combined with the AJCC TNM staging system showed a stronger power for DFS prediction in the ROC analysis, implying that the stage-independent IncRNA signatures may have potential to refine the current prognostic model[120].

Although these results above are promising, further studies remain necessary to make sure that the IncRNAs may provide more information than current standard diagnostic procedures.

**IncRNAs as a future therapeutic approach in CRC**

In spite of the fact that long-term rate of survival
of patients with early-phase CRC has increased dramatically over the past decades, successful therapeutic strategies for patients with advanced CRC remain limited, requiring novel aggressive therapy in addition to surgical intervention.

At present, anticancer strategies that focus on cancer-specific expression of oncogenic IncRNAs as target molecules are under development. For instance, the paternaly-imprinted, oncofetal IncRNA H19 has been found to be a promising target for CRC therapy[121], BC-819 (also termed DTA-H19) is a novel double-stranded DNA plasmid carrying the A fragment of diphtheria toxin (DTA) gene under the control of H19 promoter[122-124]. Intra-tumoral or control of fragment of diphtheria toxin (DTA) gene under the growth[65] Although the nucleic acid-based approach cell line HCT-116 significantly suppresses tumor cell cells in xenograft models or in the p53 wild-type CRC by plasmid expression vector into CRC Loc285194 difficulties to overcome. For example, the challenge of lncRNAs are required. achieving a better delivery system with efficacy, rigorous investigations into the therapeutic potent ial advances into medical practice, future robust and safety and specificity remains to be solved.

Alternatively, genetic therapies may be designed to treat CRC by manipulating the expression of IncRNAs. For instance, an RNA duplex of siRNAs exhibits high knockdown efficacy of many oncogenic IncRNAs in CRC cells. Silencing of IncRNA expression via administration of specific siRNA oligonucleotides targeting the oncogenic IncRNA CRNDE[48], HOTAIR[59, 111], CCAT2[46], Ptv1 oncogene (PVT1)[58], and uc.73A[59] sequences have been confirmed to exhibit significant anticancer effects, such as decreasing invasion or proliferation either in vivo or in vitro. In addition to knockdown of the oncogenic IncRNAs, restoring endogenous tumor suppressive IncRNAs function in patients with CRC may also be beneficial. One example is in the case of the p53-induced IncRNA Loc285194. Delivery of Loc285194 by plasmid expression vector into CRC cells in xenograft models or in the p53 wild-type CRC cell line HCT-116 significantly suppresses tumor cell growth[65]. Although the nucleic acid-based approach for CRC treatment is in the development phase, the IncRNA-based therapeutics for CRC still has several difficulties to overcome. For example, the challenge of achieving a better delivery system with efficacy, safety and specificity remains to be solved.

To implement these experiment-based research advances into medical practice, future robust and rigorous investigations into the therapeutic potential of IncRNAs are required.

Conclusions

To date, we and others have taken important initial steps on the road to figure out the biological functions of IncRNAs in CRC. Given the exponential growth of newly discovered cancer-associated IncRNAs, future studies must specifically address the super-secondary structure (motifs), secondary structure, or tertiary structure of IncRNAs. As we move forward, we will refine our global view of the gene regulatory network involving IncRNAs and ultimately establish more effective measures or strategies for the field of IncRNA as a potential biomarker for clinical diagnosis, prognosis and therapeutics in patients with CRC. However, further study employing a greater number of clinical samples will be required to confirm the sensitivity and specificity for these IncRNA as clinical biomarkers in CRC patients.

Abbreviations

IncRNA, long noncoding RNA; CRC, colorectal cancer; CCAL, colorectal cancer-associated IncRNA; AP-2α, activator protein 2α; CCAT1, colon cancer-associated transcript-1; MYC, v-myelocytomatisis viral oncogene homolog; CRNDE, colorectal neoplasia differentially expressed; EGFR, epidermal growth factor receptor; E2F4, E2F transcription factor-4; HOTAIR, Hox transcript antisense intergenic RNA; PRC2, polycomb repressive complex-2; EMT, epithelial-mesenchymal transition; HULC, hepatocellular carcinoma up-regulated long non-coding RNA; KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; LIT1, long QT intronic transcript-1; LOI, loss of imprinting; KvDMR1, KCNQ1 opposite strand/antisense transcript 1; TGF-β, transforming growth factor-beta; IncRNA-ATB, IncRNA-activated by TGF-β; MALAT1, metastasis associated lung adenocarcinoma transcript-1; ZEB1, zinc finger E-box binding homeobox-1; ncNRFR, non-coding Nras functional RNA; PCAT1, prostate cancer associated transcript-1; PVT1, Ptv1 oncogene; CUDR, urothelial cancer associated-1; BANCR, BRAF activated non-coding RNA; p21, cyclin-dependent kinase inhibitor 1A; CAHM, colorectal adenocarcinoma hypermethylated; IncRNA-LET, IncRNA low expression in tumor; hnRNPK, heterogeneous nuclear ribonucleoprotein K; Loc285194, also known as TUSC7, tumor suppressor candidate 7; PTENP1, phosphatase and tensin homolog pseudogene 1; PTEN, phosphatase and tensin homolog; miRNA, microRNA; MEG3, maternally expressed gene-3; TP53, tumor protein p53; MDM2, mouse double minute 2 homolog; ncRAN, non-coding RNA expressed in aggressive neuroblastoma; BA318C17.1, also known as MACROD2-AS1, MACROD2 antisense RNA 1; H19, imprinted maternally expressed transcript; RB, retinoblastoma 1; PRNCR1, prostate cancer non-coding RNA-1; SNPs, single nucleotide polymorphisms; XIST, X-inactive Specific transcript; N/A, Not applicable.
Acknowledgments

This work was sponsored by grants from the National Natural Science Foundation of China (No. 81372615), the Fudan Outstanding Young Talent Training Plan (YJYQ201601), and Sponsored by Shanghai Pujiang Program (17PJ007).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA biology. 2012; 9: 703-19.

2. Skipper M. Genomics: 'users' guide to the human genome. Nature reviews Genetics. 2012; 13: 678.

3. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annual review of biochemistry. 2012; 81: 145-66.

4. Collins LJ, Penny D. The RNA infrastructure: dark matter of the eukaryotic biology. Cell. 2011; 147: 1537-50.

5. Cech TR, Steitz JA. The Noncoding RNA Revolution-Trashing Old Rules to Structure, Evolution, and Expression. Genome research. 2012; 22: 1775-89.

6. Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012; 61: 1447-53.

7. Xu MD, Qi P, Du X. Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014; 13 Suppl 2: S7.

8. Hung T, Chang HY. Long noncoding RNA in genome regulation: prospects and mechanisms. RNA biology. 2010; 7: 582-5.

9. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA. 2010; 16: 925-33.

10. Barquist L, Tate J, Eberhardt R, Daub J, Nawrocki EP, et al. Rfam: a database of RNA families structure, evolution, and expression. Nucleic acids research. 2013; 41: D246-51.

11. Ning S, Zhao Z, Ye J, Wang P, Zhi H, Li R, et al. LincSNP: a database of linking non-coding SNPs to human large intergenic non-coding RNAs. BMC bioinformatics. 2014; 15: 152.

12. Burge SW, Daub J, Eberhardt R, Tate J, Barquist L, Nawrocki EP, et al. Rfam: a database of non-coding RNA families from 235 species. Nucleic acids research. 2013; 41: D124-D126.

13. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. GENCODE: reference human long noncoding RNA annotation and comparison to ENCODE. Genome biology. 2012; 13: R63.

14. Amaral PP, Clark MB, Gascoigne DK, Dinger ME, Mattick JS. IncRNAAtlas: a reference database for long non-coding RNAs. Nucleic acids research. 2011; 39: D146-D151.

15. Li H, Jiang H, Zhao H, Xu H. ChIPBase: a database for ChIP-Seq data. Nucleic acids research. 2013; 41: D127-D128.

16. Guttman M, Amit I, Oren M, Lickman T, Her Kadari R, Thomson J, et al. Principles of long noncoding RNA gene expression. Science. 2010; 329: 1354-9.

17. Fearon ER. Molecular genetics of colorectal cancer. Annual review of medicine. 1999; 50: 119-35.

18. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Nature reviews Genetics. 2008; 9: 701-13.

19. Liao Q, Xiao H, Bu D, Xie C, Miao R, Luo H, et al. reFeNAs: a web server for functional annotation of long non-coding RNAs. Nucleic acids research. 2011; 39: W185-W189.

20. Gellert P, Ponomareva Y, Braun T, Ulich A. Nonco德尔: a web interface for exon array-based detection of long non-coding RNAs. Nucleic acids research. 2013; 41: e20.

21. Dinger ME, Pang KC, Mercer TR, Crowe ML, Grimmond SM, Mattick JS. NRED: a database of long noncoding RNA expression. Nucleic acids research. 2013; 41: D129-D136.

22. Sun K, Chen X, Jiang P, Song X, Wang H, Sun H. 6eRNA: identification of long intergenic non-coding RNA transcripts from transcriptome sequencing data. BMC genomics. 2013; 14 Suppl 2: S7.

23. Kam Y, Rubinstein A, Naik S, Djavsarov I, Halle D, Ariel I, et al. Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-FLNA molecular beacons. Cancer letters. 2013; 330: 191-8.

24. Kogo R, Shimamura T, Mizormi K, Kawahara K, Imoto S, Katayama T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer research. 2011; 71: 6260-2.

25. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010; 31: 350-8.

26. Xiong JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, et al. Human colorectal cancer-specific CCAT1-lncRNA regulates long-range chromatin interactions at the MYC locus. Cell research. 2014.

27. Nissan A, Steđanovíc A, Mittrand-Fursterman S, Halle D, Grinbaum R, Roistacher M, et al. Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues. International journal of cancer Journal international du cancer. 2012; 130: 1598-606.

28. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, Akiyama S, et al. Loss of H19 imprinting in esophageal cancer. Cancer research. 1996; 56: 480-2.

29. Ma Y, Yang Y, Wang F, Feng MP, Wei Q, Zhang P, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/beta-catenin signalling pathway via suppression of activator protein Zebpa. Gut. 2015.

30. Alayian B, Ilyayev N, Steđanovíc A, Izjadi M, Roistacher M, Pavlov V, et al. Differential expression of colon cancer associated transcripted (CCAT1) along the colorectal adenocarcinoma sequence. BMC cancer. 2013; 13: 196.

31. Ling H, Spizzo R, Atlanzi Y, Nicoloso M, Shimizu M, Redis RS, et al. CCAT2, a novel non-coding RNA mapping to 9q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome research. 2013; 23: 1446-61.

32. Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, et al. Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes & Cancer. 2011; 2: 829-40.

33. Ellis BC, Graham LD, Molloy PL, CRNDE, a long non-coding RNA response to insulin/IGF signaling, regulates genes involved in central metabolism. Biochimica et biophysica acta. 2014; 1843: 372-86.

34. Yochum GS, Cleland R, McKinney S, Goodman RH. An antisense transcript induced by Wnt/beta-catenin signaling decreases E2F4. The Journal of biological chemistry. 2007; 282: 871-8.

35. Hsu Y, Kang Y. A New Lnc in Metastasis: Long Noncoding RNA Mediates the ProMetastatic Functions of TGF-beta. Cancer cell. 2014; 25: 557-69.

36. Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi M. Highly Upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. European journal of gastroenterology & hepatology. 2009; 21: 688-92.

37. Tanaka K, Shigeta G, Meguro M, Mitsuya K, Oshimura M, Kawasaki H. Loss of insulin-like growth factor 1 gene induced by Wnt/beta-catenin signaling decreases E2F4. The Journal of biochemistry. 2001; 60: 268-73.

http://www.jcancer.org
53. Nakano S, Murakami K, Meguro M, Soejima H, Higashimoto K, Urano T, et al. Expression profile of LIT1/ KCNQ1OT1 and epigenetic status at the KvDMRI in colorectal cancers. Cancer science. 2008; 97: 1147-54.

54. Yuan JH, Yang W, Fang F, Ma JZ, Guo YJ, Tao QF, et al. A Long Noncoding RNA Activated by TGF-beta Promotes the Invasion-Metastasis Cascade in Hepatocellular Carcinoma. Cancer cell. 2014; 25: 666-81.

55. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important role in functional and molecular colorectal cancer metastasis. International journal of oncology. 2011; 39: 169-75.

56. Franklin JL, Rankin CR, Levy S, Snoddy JR, Zhang B, Washington MK, et al. Malignant transformation of colonic epithelial cells by a colon-derived long non-coding RNA. Biochemical and biophysical research communications. 2013; 440: 99-104.

57. Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Medical oncology. 2012; 3: 50-58.

58. Takashashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, et al. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. British journal of cancer. 2014; 110: 164-71.

59. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, et al. Ultraconserved regions encoding ncRNAs are altered in human leukaemias and carcinomas. Cancer cell. 2007; 12: 215-29.

60. Tsang WP, Wong TW, Cheung AH, Co CN, Kwok TT. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. Rna. 2007; 13: 890-8.

61. Shi Y, Liu Y, Wang J, Jie D, Yun T, Li W, et al. Downregulated Long Noncoding RNA BANCR Promotes the Proliferation of Colorectal Cancer Cells via Downregulation of p2i Expression. PloS one. 2015; 10: e0122679.

62. Pedersen SK, Mikkelsen SM, Graham LD, Matthew A, Thomas ML, Baker RT, et al. CAHM, a long non-coding RNA gene hypermethylated in colorectal neoplasia. Epigenetics: official journal of the DNA Methylation Society. 2014; 9: 717-725.

63. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Molecular cell. 2013; 49: 1085-96.

64. Zhao H, Fesler A, Chee K, Rodstad O, Flatmark K, Ju J. Clinical significance of long intergenic non-protein-coding RNA-p21 in colorectal cancer. Clinical colorectal cancer. 2013; 12: 261-6.

65. Liu Q, Huang J, Zhou N, Zhang Z, Zhang L, Li Z, et al. LincRNA loc285194 is a p53-regulated tumor suppressor. Nucleic acids research. 2013; 41: 4976-87.

66. Qin SJ, Huang D, Wei P, Tan C, et al. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. Journal of translational medicine. 2013; 11: 122.

67. Zhou Y, Zhong W, Yang Z, Zhang X, Batista DL, Geijn R, et al. Activation of p53 by MECDI non-coding RNA. The Journal of biological chemistry. 2007; 282: 24731-42.

68. Menigatti M, Staiiano T, Mander CN, Bauerfeind P, Komljenovic A, Robinson M, et al. Epigenetic silencing of monoclonally methylated mRNA loci in precancerous colorectal lesions. Oncogenesis. 2013; 2: e56.

69. Qi P, Xu MD, Ni SJ, Shen XH, Wei P, Huang D, et al. Down-regulation of ncRNAs, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Molecular carcinogenesis. 2014.

70. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A non-coding RNA sponge in colorectal cancer. Oncotarget. 2015.

71. Shi Y, Liu Y, Wang J, Jie D, Yun T, Li W, et al. Downregulated Long Noncoding RNA BANCR Promotes the Proliferation of Colorectal Cancer Cells via Downregulation of p2i Expression. PloS one. 2015; 10: e0122679.

72. Yoshimizu T, Miroglio A, Ripoche MA, Gabory A, Vernucci M, Riccio A, et al. The H19 locus acts in vivo from a structural perspective. Oncogene. 2006; 25: 7482-91.

73. Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, et al. The level of lncRNA MALAT-1 is increased in colorectal cancer and breast cancer. Journal of cancer. 2013, Vol. 8

74. Franklin JL, Rankin CR, Levy S, Snoddy JR, Zhang B, Washington MK, et al. Malignant transformation of colonic epithelial cells by a colon-derived long non-coding RNA. Biochemical and biophysical research communications. 2013; 440: 99-104.

75. Wilkins JA, Sansom OF. C-Myc is a critical mediator of the phenotypes of Apc(min) mouse. Oncogene. 2006; 25: 7482-91.

76. Pachnis V, Belayew A, Tilghman SM. Locus unlinked to alpha-fetoprotein gene is expressed in neural crest derivatives and contributes to neural tube closure and cranial nerve development. Proceedings of the National Academy of Sciences of the United States of America. 1984; 81: 5523-7.

77. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-67.

78. Wilkins JA, Sansom OF. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer research. 2008; 68: 4963-6.

79. Kimmelman D, Xu W. beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene. 2006; 25: 7482-91.

80. Sansom OF, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, et al. Loss of Apo in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes & development. 2004; 18: 1385-90.
113. Meyer KB, Maia AT, O'Reilly M, Ghousaini M, Prathalingam R, Porter-Gill P, et al. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS genetics. 2011; 7: e1002165.

114. Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2013; 26: 155-65.

115. Cheng J, Kapravov P, Drenkow J, Dike S, Brubaker S, Patel S, et al. Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science. 2005; 308: 1149-54.

116. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS medicine. 2013; 10: e1001453.

117. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. Biomarkers in precision therapy in colorectal cancer. Gastroenterology report. 2013; 3: 166-83.

118. Nitsche U, Maak M, Schuster T, Kunzli B, Langer R, Slotta-Huspenina J, et al. Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective. Annals of surgery. 2011; 254: 793-800; discussion -1.

119. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469: 343-9.

120. Hu Y, Chen HY, Yu CY, Xu J, Wang JL, Qian J, et al. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer. Oncotarget. 2014; 5: 2230-42.

121. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Current opinion in molecular therapeutics. 2010; 12: 607-16.

122. Hasenpusch G, Pleifer C, Aneja MK, Wagner K, Reinhardt D, Gilon M, et al. Aerosolized BC-819 inhibits primary but not secondary lung cancer growth. PLoS one. 2011; 6: e20760.

123. Amit D, Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. Journal of translational medicine. 2010; 8: 134.

124. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. Journal of translational medicine. 2009; 7: 69.

125. Sorin V, Ohana P, Mizrahi A, Matouk I, Birman T, Hochberg A, et al. Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver. International journal of oncology. 2011; 39: 1407-12.